Long-term safety study of NBI-1117568 in adults with schizophrenia
Tests NBI-1117568 safety over time in adults with schizophrenia.
Plain-language title generated from the registry record
Registry title: NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Key facts
- Where
- Atlanta, Atlantis, Austin, Aventura, Bellevue, Boston, Bryant, Cedarhurst, Cerritos, Chicago, Chino, Culver City, Decatur, DeSoto, Doral, Flowood, Gaithersburg, Garden Grove, Hollywood, Houston, La Habra, Lemon Grove, Little Rock, Maitland, Marlton, Miami, Miami Lakes, New York, North Canton, Oak Brook, Oceanside, Orem, Peachtree Corners, Philadelphia, Pico Rivera, Riverside, San Diego, Sherman, St Louis, Staten Island, Tampa, The Bronx, Torrance, Watertown, West Hills, and West Palm Beach, United StatesSee the 47 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07114874, who can take part
Where in United States
- AtlantaAtlanta, United StatesTaking people
- AtlantisAtlantis, United StatesTaking people
- AustinAustin, United StatesTaking people
- AventuraAventura, United StatesTaking people
- BellevueBellevue, United StatesTaking people
- BostonBoston, United StatesTaking people
- BryantBryant, United StatesTaking people
- CedarhurstCedarhurst, United StatesTaking people
- CerritosCerritos, United StatesTaking people
- ChicagoChicago, United StatesTaking people
- ChinoChino, United StatesTaking people
- Culver CityCulver City, United StatesTaking people
- DecaturDecatur, United StatesTaking people
- DeSotoDeSoto, United StatesTaking people
- DoralDoral, United StatesNo longer taking part
- FlowoodFlowood, United StatesTaking people
- GaithersburgGaithersburg, United StatesTaking people
- Garden GroveGarden Grove, United StatesTaking people
- HollywoodHollywood, United StatesTaking people
- HoustonHouston, United StatesTaking people
- La HabraLa Habra, United StatesTaking people
- Lemon GroveLemon Grove, United StatesTaking people
- Little RockLittle Rock, United StatesTaking people
- MaitlandMaitland, United StatesTaking people
- MarltonMarlton, United StatesTaking people
- MiamiMiami, United StatesTaking people
- Miami LakesMiami Lakes, United StatesTaking people
- New YorkNew York, United StatesTaking people
- North CantonNorth Canton, United StatesTaking people
- Oak BrookOak Brook, United StatesTaking people
- OceansideOceanside, United StatesTaking people
- OremOrem, United StatesTaking people
- OremOrem, United StatesTaking people
- Peachtree CornersPeachtree Corners, United StatesTaking people
- PhiladelphiaPhiladelphia, United StatesTaking people
- Pico RiveraPico Rivera, United StatesTaking people
- RiversideRiverside, United StatesTaking people
- San DiegoSan Diego, United StatesTaking people
- ShermanSherman, United StatesTaking people
- St LouisSt Louis, United StatesTaking people
- Staten IslandStaten Island, United StatesTaking people
- TampaTampa, United StatesTaking people
- The BronxThe Bronx, United StatesTaking people
- TorranceTorrance, United StatesTaking people
- WatertownWatertown, United StatesTaking people
- West HillsWest Hills, United StatesNo longer taking part
- West Palm BeachWest Palm Beach, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Neurocrine Biosciences
- Trial code
- NCT07114874EU 2025-521216-19-00
- Record updated
- 25 September 2026
- Original description
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.Read full original descriptionShow less
A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
Inclusion: Participant has a primary diagnosis of schizophrenia; Participants taking prohibited medications, including antipsychotics, must discontinue before study participation; Participant must reside in a stable housing situation.
Exclusion: Participant has a diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening; Participant has a positive alcohol test or drug screen for disallowed substances; Participant has known hypersensitivity to any component of the formulation of NBI-1117568; Participant has an unstable or poorly controlled medical condition or chronic disease; Participant has a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the participant is not capable of adhering to the protocol requirements; Note: Other protocol-specified inclusion/exclusion criteria may apply; Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others.